Semaglutide generics set to enter the Canadian market by 2026 after Novo Nordisk failed to maintain key patent | Speculation ...

"I’m sure someone’s lost their job," said the CEO of Sandoz, which has now filed to launch a generic GLP-1 in Canada next ...

Novo Nordisk (NYSE: NVO) has permanently forfeited Canadian patent protection for semaglutide—the blockbuster active ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

During a session at the Heart in Diabetes CME Conference, speakers highlighted four papers recently published in Circulation ...

FDA seizes hundreds of fake Ozempic units from US supply after Novo Nordisk alerts regulators to counterfeit semaglutide ...

“The legal tangle over Novo Nordisk’s weightloss and diabetes drug semaglutide will be a “test case” of sorts, say intellectual property (IP) experts, as more Indian drugmakers wait in the ...

A legal tangle hovers over Novo Nordisk’s diabetes and weightloss drug semaglutide, just weeks ahead of the possible launch of its injectible version Wegovy in India. Semaglutide is the active ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy. Novo Nordisk has announced ...

Novo Nordisk is the Danish Pharma giant whose stock price rose from ~$50 in late-2022, to >$140 in mid-2024, largely on account of one drug - its glucagon-like peptide 1 drug, semaglutide.

Novo Nordisk is making yet another bet on obesity ... Septerna’s binding site has 80% to 90% sequence similarity across the three receptors, versus 40% to 60% for rival assets.

created by Danish pharmaceutical company Novo Nordisk. The drug soared in popularity by offering a quicker fix to obesity, which is a growing health concern around the globe. Some people also take ...